Radical prostatectomy (RP) is a commonly performed procedure for the management of prostate cancer. While documented oncologic outcome for early stage disease is excellent, functional impairments such as incontinence and erectile dysfunction (ED) are common after the procedure. Recent evidence has implicated cavernous nerve damage and subsequent corporal oxygen deprivation, as well as corporal inflammation, in the pathogenesis of post-RP ED. Targeted therapies such as oral phosphodiesterase-5 inhibitors, mechanical vacuum erection devices, local alprostadil delivery and testosterone replacement (for hypogonal patients) have demonstrated some efficacy in the management of post-RP ED. This review aggregates much of the recent data in support of these therapies and critically reviews them. The article then presents tools to assess patients and partner sexual function to aid in identifying and monitoring post-RP ED. Finally, the article describes a protocol in use at Baylor College of Medicine as a guide toward the development of a protocol for erectile preservation (EP). The purpose of this work is to educate clinicians on emerging concepts in EP and provide an implementable protocol for use in practice.
Introduction
Prostate cancer, the most common non-dermatological malignancy in men in the United States with an annual incidence of approximately 220 000, is responsible for almost 30% of cancer diagnoses and 9% of cancer-related mortality in US men. 1 Definitive therapeutic strategies include radical prostatectomy (RP) and radiation therapy. The number of RPs performed per annum is estimated at 110 000 in the United States alone. 2 Recent advances in screening and early detection of prostate cancer have yielded excellent oncologic outcomes for low-risk patients and shifted the focus of surgeons to enhance functional outcomes for patients undergoing RP. 3, 4 Such functional outcomes include recovery of urinary continence and erectile function.
While several factors influence post-RP erectile function recovery, pre-operative erectile function and nerve sparing (NS) status are critical predictors. Tal and coworkers identified the aggregate recovery rate of erectile function after surgery at approximately 60%. Even within this fraction of patients, a large variability in the quality of erections likely exists because of the subjective nature of assigning a binary response to the presence of satisfactory function.
In general, erectile dysfunction (ED) and reduced sexual satisfaction have a negative impact on quality of life. 5 Various studies assessing the efficacy of interventions to treat ED include quality of life measures as secondary outcomes. Importantly, studies have consistently indicated that erectile function correlates with favorable quality of life outcomes in patients. 5, 6 Perhaps an even higher impact observation is that the quality of erectile function correlates with emotional well being. 7 Interestingly, data regarding management of patients after RP remain fragmented and inconsistent. A study of French urologist's suggests that only a minority actually provide formal post-RP therapy directed at sexual function outcomes. 8 The questionnaire-based study found that only 38% of urologists prescribed a systematic program for patients despite the fact that the overwhelming fraction of urologists assesses pre-RP sexual function. The most commonly used therapy was injection based, perhaps suggesting that other effective modalities for post-RP therapy would shift this dynamic. Physicians familiar with sexual medicine as a discipline are more likely to implement post-RP therapy targeted at preservation of erectile function, supporting the role for increased awareness of this concept. 9 Given the impact of RP on erectile function, it is prudent for physicians to implement strategies related to minimizing and reversing post-RP ED. This requires both a thorough understanding of the pathogenesis of post-RP ED and the role of various therapies to mechanistically impact the process. Clinically, physicians require treatment strategies and assessment tools to capture response and satisfaction. This review article attempts to synthesize the literature on the various modalities of post-RP therapy targeted for recovery of erectile function. We discuss the clinical strategies designed to overcome the non-surgical factors believed to precipitate the development of post-RP ED. Additionally, we present some commonly used validated instruments that are useful to define baseline erectile function and follow response to therapy.
Physiologic mechanism of post-RP ED
RP is believed to impact long-term erectile function by interfering with the neurological mechanisms that facilitate cavernosal oxygenation. While the mechanism of such neurological disruption or trauma (neuropraxis) is not entirely clear, hypotheses include direct trauma during surgery (for example retraction injury), damage from tissue electrocautery, disruption of the neural vasculature and generalized local inflammation associated with the procedure. 10 Regardless of the etiology of this neurological damage, the functional consequences of impaired parasympathetic penile function manifest themselves as ED.
This neuropraxia results in a post-procedural ED with associated cavernosal hypoxia. 11 Whereas this issue underlies early post-operative ED, fibrosis ensues and is marked by the presence of transforming growth factor b, a marker of chronic inflammation and fibrosis. 12, 13 Additionally, anti-fibrotic mediators such as prostaglandin E1 (PGE1) and cyclic adenosine monophosphate are under-represented during this process. Therefore, while neuropraxia may be reversible, penile fibrosis permanently damages cavernosal function and produces chronic ED. Furthermore, this destructive cycle leads to cavernosal smooth muscle apoptosis. 13 In response to these hypoxic conditions, the tissues upregulate the nitric oxide pathway, mediated by inducible nitric oxide synthase and cyclic guanosine monophosphate to attempt to improve penile blood flow.
Clinically, the impact of this chronic inflammatory response to cavernosal hypoxia is manifested by long-term collagen deposition and reduced smooth muscle.
14 In addition to vaso-occlusive disease, venous leak develops due to the reduction in corporal elasticity. Over time, these patients present with increasing rates of ED. Therefore, while occasional use erectogenic pharmacotherapy will likely produce a transient erection, especially early after surgery, there is long-term deterioration of the normal physiologic processes involved in this process.
This broad overview of mechanisms predisposing post-RP patients to ED suggests multiple points of intervention to prevent the development of ED in these patients. Most importantly, tissue oxygenation may reduce the prevalence of chronic inflammation and cavernosal fibrosis. Interestingly, hyperbaric oxygen therapy in an animal model of cavernous nerve injury has not been shown to significantly reverse or minimize this process, suggesting that there are multiple mechanisms involved. 15 Secondarily, cytokine mediators of tissue fibrosis and inflammation are targets for pharmacotherapy aimed at preserving cavernosal tissue integrity. The concept of erectile preservation (EP) is premised on minimizing the factors that impair long-term erectile function. Therefore, therapeutic strategies must target the aforementioned mechanisms to provide patients with optimal functional outcomes.
Rationale for erectogenic pharmacotherapy in RP patients
Terminology The use of erectogenic agents after prostatectomy has traditionally been referred to as penile rehabilitation. However, rehabilitation implies the reversal of functional deterioration. In contrast, the objective in patients with a planned RP is the preservation of pre-operative erectile function. In fact, several programs that initiate the use of erectogenic pharmacotherapy in this patient population begin in the weeks before surgery. 16 For this reason, the program is referred to as EP rather than penile rehabilitation. Perhaps, these terms are similar in their intent but the term 'EP' suggests the desired outcome to patients (for example a short-term therapeutic bridge directed toward the recovery of natural erections) and the urologic team to promote awareness and compliance. Additionally, the protocol allows patients to have medication-assisted erections regardless of natural erectile capacity, thus preserving erectile function throughout their recovery.
Phosphodiesterase-5 inhibitors
The use of phosphodiesterase-5 (PDE-5) inhibitors is, in general, the most common therapy offered to Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al patients after prostatectomy. 8, 9 The value added by offering PDE-5 inhibitors to post-RP patients is twofold: it supports a patients' ability to achieve an erection after surgery and contributes to the longterm recovery of erectile function. While the former property of PDE-5 inhibitors has been clearly established, the latter has only begun to be elucidated. This review will summarize the compelling evidence to support PDE-5 inhibitors for both these objectives, making it the cornerstone of our EP program.
Several studies have examined daily PDE-5 inhibitor therapy for post-RP patients. McCullough et al. 17 demonstrated the return of normal nocturnal penile tumescence and unassisted erectile function in patients who were treated with nightly sildenafil after RP. For the sildenafil group of patients, there was a dose-dependant improvement in recovery of nocturnal penile rigidity. Importantly, the larger trial from which this subgroup analysis is based suggests that this outcome in fact correlates with the recovery of natural erectile function (see below). 18, 19 Additionally, there was a substantial difference in the rate of recovery of erections satisfactory for sexual intercourse (for example a rate of 5 Â -7 Â ) for patients taking 50-100 mg of sildenafil nightly. However, the study was very small (N ¼ 54) and represents a subgroup analysis of a larger trial. The authors remark that, since only one patient in the placebo recovered nocturnal erectile function, the small sample size limits comparisons between groups. However, the consistent performance of the two sildenafil groups versus the control supports this therapeutic strategy in this patient population.
In a complementary study, Bannowsky et al.
20
reported the impact of nightly sildenafil on the progression of international index of erectile function (IIEF) scores after RP. In this small controlled study, patients were randomized based on pre-RP IIEF scores, nocturnal erectile function, age and NS status. After surgery, patients experienced a decline in IIEF scores of over 75% on average at the 6-week assessment. Steady increases in IIEF scores were observed in both groups thereafter, with a statistically significant increases in IIEF scores observed at 36 and 52 weeks for PDE-5 inhibitor patients over control. The fact that a small study was able to show a statistically significant difference in outcomes suggests that the effect of sildenafil on sexual health is very favorable. However, a larger study would improve confidence in these results. Definitive evidence to support use of nightly PDE-5 inhibitor therapy has been derived from the abovereferenced randomized, placebo-controlled trial by Padma-Nathan et al. 19 In the study, the authors compared natural erectile function after an 8-week washout period subsequent to 36 weeks of nightly sildenafil therapy. Patients reported a return of normal 'spontaneous' erections at a 7 Â rate over control patients (4% versus 27%) based on IIEF scores (for questions 3 and 4) X8 when also responding positively to the question 'were erections good enough for satisfactory sexual activity?'. In general, IIEF scores for the sildenafil patients were just below 50% greater than placebo patients (13.1 versus 8.8). Interestingly, the rate of recovery for patients in the control arm was surprisingly low and the authors were unable to clearly explain why. Irrespective of this absolute observation, the relative performance of the study group is very impressive and compelling. Of note, the doses of sildenafil were between 50 and 100 mg over the course of therapy.
Montrosi and McCullough 21 performed a comprehensive and elegant meta-analysis examining the role of PDE-5 inhibitor therapy after surgery. The authors reviewed studies of post-RP patients, where PDE-5 inhibitor therapy was an independent variable in the analysis. Pooling all results together yielded an overall response rate of 35% with considerable variability (95% confidence interval: 24-48%). Noting that these data include patients sustaining varying degrees of NS during their surgery, the authors independently assessed this factor to describe responses to PDE-5 inhibitor therapy. The authors noted NS to be a very important factor in segmentation, where patients undergoing NS RP had a response rate ranging from 35 to 75% and patients whose surgery was non-NS ranged from 0 to 15%. The combined odds ratio for this result was determined to be 12.1. Careful analysis of the degree of NS demonstrated statistically comparable rates of response between unilateral and bilateral NS, but the range of outcomes was more variable in the unilateral NS group compared with the bilateral NS group. While this study demonstrates the remarkable effectiveness of PDE-5 inhibitors after RP, particularly in patients who undergo NS surgery, there are some important weaknesses inherent in the studies comprising this meta-analysis. Only seven studies were included in the primary response analysis and only five of those commented on NS. More so, the authors' ability to distinguish between the extent of NS relied on only four studies. As is a common problem in this body of literature, the results of the study would be more compelling if a standard measure of erectile function was included in all studies. Regardless, this study was successful in definitively establishing the value of PDE-5 inhibitors for post-RP patients.
Perhaps, the least established concept is the idea that pre-RP PDE-5 inhibitor therapy adds value to EP. While no formal published data are available, some have described improvement in recovery of post-operative erectile function in animal models when PDE-5 inhibitors are used before injury. 22 Interestingly, the value of a formal EP program versus on-demand dose PDE-5 inhibitor therapy has not been definitively elucidated. Whereas the abovereferenced studies rely on some regularity in dosing Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al (for example nightly, four time per week and so on), a study by Montorsi et al. 23 was unable to demonstrate a difference in functional outcomes between patients on demand-dose PDE-5 inhibitors versus a formal EP program schedule in a three-arm controlled study. However, this study neither assessed a comprehensive EP program nor did it document compliance with regular PDE-5 inhibitor dosing. Additionally, it was composed of numerous treatment sites and did not control for surgeon skill in preserving the cavernosal nerves. Thus, this outcome cannot be extrapolated to all formal EP regimens. Despite the statistical equivalence between these two groups, each showed a dramatic improvement in erectile function compared with the control group.
The pathophysiologic modification of PDE-5 inhibitors can also be observed histologically. Mulhall et al. 24 observed the role of sildenafil in preservation of erectile function after cavernous nerve crush injury. In a rat model for cavernosal nerve injury, the authors demonstrated maintenance of cavernosal smooth muscle integrity and observed a trend in favor of improved erectile function outcomes. The authors attribute this to improved penile hemodynamics immediately after injury, thus preventing smooth muscle apoptosis with permanent damage to the tissues. Schwartz et al.
14 demonstrated the dose-dependant impact of sildenafil on corporal smooth muscle after RP. In this study, two groups (50 and 100 mg of sildenafil every other night) were biopsied at the time of RP and 6 months post-operatively. While their small study (N ¼ 21) lacks a control group because of concern for the psychological trauma associated with the 6-month post-RP biopsy, the patients in the 50-mg group maintained pre-RP corporal smooth muscle levels, whereas the patients in the 100-mg actually had a significant increase in post-RP corporal smooth muscle (as a percent of the histologic section assessed by a computer-based analysis tool). At 6 months, the overall prevalence of veno-occlusive disease in both groups was o5% (one patient). The authors comment on other reports of the chronology of post-RP veno-occlusive disease where evidence of disease is present in at least 50% of post-RP impotent patients, if not all post-RP patients, at approximately 6 months. 25, 26 Furthermore, a study by Mulhall et al. 27 suggested that rates of venoocclusive disease increased through 18 months from 14 to 50% post-RP. Vascular status was also predictive of the likelihood the patient had recovered erectile function sufficient for sexual activity; 47% of men with normal penile vascular status had recovered erections, while only 8% of patients with venous leak reported sufficient erectile function after 1 year post-RP. These two studies offer insight into the pathophysiology of post-RP ED and suggest that EP may offset some of the detrimental effects of the procedure.
For this reason, PDE-5 inhibitor therapy is the backbone of our institution's EP program. Pharmacotherapy with PDE-5 inhibitors is initiated prior to surgery given the aforementioned anecdotal reports and, consistent with many of the case series and trials reported herein, is continued throughout the duration of recovery. Low-dose PDE-5 inhibitor therapy (25 mg) is utilized given the multiple modality approach that is described below.
Intrauretheral alprostadil suppositories
Alprostadil, a PGE1 analog, is administered to patients to increase corporal oxygenation by promoting blood flow. This drug is not only most commonly administered through intracavernosal injection (ICI), but is also available in the form of an intrauretheral suppository (MUSE s , Vivus Inc., Mountain View, CA, USA). Montorsi et al. 26 reported that recovery of spontaneous erections was 250% more likely for a patient receiving alprostadil ICI compared with an untreated control. Thus, the concept of localized (for example non-systemic) penile therapy demonstrated dramatic efficacy without concern for the systemic consequences of oral pharmaceuticals.
The use of intrauretheral alprostadil suppository therapy was documented in 1997, although early results were inconsistent and not reproducible. 28, 29 Raina et al. 30 were the first to demonstrate the longterm effectiveness of this type of therapy in post-RP patients. Their analysis consisted of a retrospective review of post-RP patients 6 months after surgery who subjectively reported ED (defined as the inability to achieve vaginal penetration). Patients were told to use MUSE (titrated up to 1000 mg based on efficacy) on demand. Overall, 55% were able to achieve erections sufficient for penetration with 61% of partners reporting satisfaction with this modality of therapy. Sexual health inventory in men (SHIM) scores after MUSE use were comparable with pre-RP scores in these patients.
McCullough et al. 31 adapted the concept of nightly low-dose PDE-5 inhibitor therapy to compare the effectiveness of this commonly used approach with nightly MUSE. Patients were randomized into groups using nightly sildenafil or MUSE (125 mg titrated to 250 mg within 1 month if tolerable). The study included only men with IIEF scores of at least 26. Treatment was initiated upon catheter removal and was continued for 9 months. After a 1-month washout period where patients were instructed to attempt sexual intercourse without medication to assist with erections, demand-dose erectogenic aids (sildenafil) were provided to patients. The final assessment was conducted 11 months after initiating the protocol. IIEF score rose sequentially and were approximately 50-75% higher after treatment than at baseline. Intercourse success rates nearly doubled from the 3 months visit Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al to end of treatment, when about 50% of patients reported successful intercourse with demand-dose therapy. Importantly, all the results were statistically comparable between the two groups. Some important caveats related to this study include a 30% dropout rate of intrauretheral alprostadil suppository patients due to discomfort associated with the treatment. Additionally, medication was provided to each patient and compliance in a non-research setting may be impacted substantially by the cost of therapy. Finally, the absence of a control group precludes definitive comparison of either therapy to placebo or control. Given the recognition that PGE1 is deficient after RP-induced injury to the penile tissues, the aforementioned investigators have utilized alprostadil replacement therapy through injection or intrauretheral suppository supplementation. The study by McCullough suggests some degree of equivalence with PDE-5 inhibitor therapy.
Our protocol leverages this reported relationship with PDE-5 inhibitors to diversify therapy for post-RP patients. As with PDE-5 inhibitors, intrauretheral alprostadil is a cornerstone of the EP program, and a similar rationale toward the timing of initiation is applied. While this therapy may be too expensive for some patients, it offers a complementary mechanism of action to PDE-5 inhibitors and is thus a critical component of the program.
Vacuum erection device
The vacuum erection device (VED) functions by creating a negative pressure gradient around the penis, drawing blood into the corporal bodies and producing an erection. The suction produces the functional benefit of the VED and a patient can place a constriction ring at the base of the penis to siphon off venous return enabling sexual performance. While VED use is an established means of treating ED in the general population, its use in post-RP patients is less well established. 32, 33 The absolute value of a VED after RP was examined by Raina et al. 34 in a relatively large trial comparing VED usage to no intervention in 109 post-RP patients. After 9 months, IIEF-5 (SHIM) scores for patients in the VED group more than tripled (4.8-16.0). Additionally, 32% of patients in the VED group reported return of spontaneous erectile function with more than half of these men (52%) reporting erections sufficient for penetration. These data compare with a 37% recovery rate for non-VED patients, although only a small fraction of these patients had sufficient rigid erection for intercourse (29%). And, while IIEF-5 score changes are not available because baseline data are not reported, post-study scores are reported as 11.2. The study also assessed satisfaction with penile length in both groups, reporting an incomparable 65% satisfaction in the VED group (23% reported absolute length decreases) versus a 63% prevalence of patients reporting decrease in length in the non-VED group. There are several important flaws with the study related to inclusion criteria and the ability to compare reported results. First, the study combined patients with NS and non-NS RP. It is inconceivable that the aggregate numbers can provide prognostic value or be objectively meaningful since these patients had a poor prognosis to begin with. Additionally, there was an 18% dropout rate in the VED group, suggesting a selection bias in the reported results. Finally, the authors report satisfaction with length parameters in VED patients but seemingly compare this with the observation to the rate of absolute length declines in non-VED patients; satisfaction of this latter cohort is neglected.
Kohler et al. 35 conducted a randomized study of scheduled daily VED use versus on-demand usage for the first 6 months after RP. A subsequent crossover for the latter group was then implemented, so the latter 6 months of the study consisted of all patients using the device twice daily in back-toback 5-min increments. The study suggested that use of VED substantially improved IIEF scores and stretched penile length. Additionally, after the first 6 months of the study (when all patients were merged into the scheduled VED use protocol), the differences between the two groups diminshed substantially. The authors note that their study suggests early implementation of VED therapy after RP as it improves sexual function and stretched penile length. However, there is no physiologic rationale for the findings of this study, particularly given that VED-induced penile blood flow is said to have the same oxygen tension as venous blood. 36 The authors suggest that the mechanism may somehow be related to amelioration of penile apoptosis, but penile hemodynamics with VED would not support this conclusion. Additionally, patients in both groups were noted to have IIEF declines from about 20 to 10 from pre-RP IIEF scores to initiation of the study. Scores were then maintained in VED patients, but declined in the control group. It is unclear why scores would decline in this latter group at 1 month when previously described data clearly present an upward trend in IIEF scores at this time point. With respect to penile length preservation, the mechanism of the VED is unclear. This result alone would not justify use in an EP program but suggests a complementary role for VED therapy rather than utilizing it as monotherapy for post-RP patients.
Perhaps, the most relevant published experience with the VED was conducted by Raina et al. who looked at the incremental value of including a PDE-5 inhibitor in combination with VED usage. As a subgroup analysis of their previously described study, the group examined VED usage alone compared with VED þ sildenafil (100 mg, 1-2 h before sexual intercourse) with respect to functional ability Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al to penetrate, rigidity (from both the patient and partner perspective) and SHIM scores. Seventyseven percent of patients initiated on combination therapy and are the basis for comparative assessment. All these domains experienced a 20-40% increase in satisfaction with the addition of sildenafil. One critical limitation when comparing the two group in this study is that these patients were offered a PDE-5 inhibitor only when dissatisfied with their VED alone, thus creating an adverse selection bias for the control group in this subgroup analysis. However, because almost 50% of patients who initiated a VED reported dissatisfaction early on, combination therapy was used in a large fraction of the overall sample. These results suggest that the VED may have a complementary role in EP and we utilize it in our program for this reason.
Consistent with our philosophy on multi-modality therapy, the VED offers a non-invasive means of achieving enhanced penile oxygenation without the exclusion of other treatments. Additionally, it is the most cost-effective therapy given the absent marginal cost of usage and the ability to immediately achieve, for some, an erection sufficient for sexual function almost immediately. While we do not utilize this therapy alone, it offers a practical and supportive complement to the previously described pharmacotherapeutic regimen.
Intracavernosal injections
Among the most established strategies for producing an erection in a patient with ED is ICI. As has been discussed, Montorsi et al. 26 introduced alprostadil ICI therapy in post-RP patients in a 1997 study that altered the way clinicians managed post-RP patients. Patients who used penile injections three times per week for 12 weeks after RP were 3.5 times more likely to have erections sufficient for erectile function. Although this study changed the way patients are managed after RP, there are several important limitations for inclusion and assessment, especially because ED therapy was in its infancy and validated assessment tools did not exist. Additionally, confounders for post-RP ED (for example NS) were not well described and surgical techniques have since evolved with the introduction of advanced laparoscopic and robotic techniques.
Advances in the physiologic awareness of penile blood flow dynamics has prompted a change from alprostadil-based ICI to trimix, a mixture of papaverine (30 mg ml -1 ), phentolamine (1 mg ml -1 ) and PGE1 (10 mg ml -1 ). This combination of therapies is typically used for ICI therapy, as it is inexpensive and highly effective.
Mulhall et al. 37 conducted a non-randomized study to assess the value of erectogenic pharmacotherapy on medication assisted and unassisted erections after RP. Patients were required to commit to a 12-month protocol premised on PDE-5 inhibitors with subsequent transition to ICI for nonresponders. Their results were compared with patients who did not enroll in the formal protocol. Seventy-seven percent of protocol patients required ICI. Results at 18 months suggested substantial improvements for the protocol group (for example 77% using ICI and 23% using a PDE-5 inhibitors three times per week) versus the control with respect to (1) the recovery of spontaneous erections (52% versus 19%), (2) response to sildenafil (64% versus 24%) and (3) response to ICI (95% versus 76%). This suggests that, for non-responders to PDE-5 inhibitors, ICI is valuable in restoring the ability to recover medication-assisted erectile function in almost all patients. An important limitation to this study is that recruitment into the treatment group was voluntary and the results may be confounded by selection bias toward patients more likely to be compliant with EP, who had greater pre-RP sexual function, or were more likely to recover natural erectile function for other reasons.
While ICI is clearly a pillar of any effective EP program, clinicians should aggressively assess compliance since documented compliance rates have been less than desirable. 38 This will maximize the opportunity for clinically desirable outcomes. In our program, ICI is used for non-responsive patients or those desiring to switch to this modality of therapy in lieu of intrauretheral alprostadil suppositories. The documented efficacy and immediacy of this therapy are attractive, although it is not introduced too early in the course of therapy because of psychosexual concerns associated with self-administered penile injections.
Testosterone replacement
In order to ensure effective recovery of erectile function after RP, it is clear the penile tissue health is a critical factor to both enable natural erectile function and support the mechanisms of some of the aforementioned agents. As has been previously discussed, the nitric oxide pathway is an essential signal driving erectile function by promoting penile blood flow. An elegant animal model used by Marin et al. 39 demonstrated the role of testosterone in supporting the function of nitric oxide synthase: normal function was restored in castrated rates only after testosterone replacement. Other studies have shown a direct correlation between testosterone and PDE-5 levels, suggesting that testosterone is involved in overall penile smooth muscle homeostasis. 40 That is, testosterone regulates nitric oxide and PDE-5 in corporal smooth muscle. Perhaps, this balance is important to erectile function or the general health of the penile tissues.
Androgen deprivation has also been shown to promote adipocyte accumulation in the cavernosal tissues. 41 Traish et al. performed a simple and elegant experiment with control and orchiectomized rabbits. Their results demonstrated that study group animals developed pockets of adipocytes throughout the cavernosal smooth muscle matrix. Mechanically, it is conceivable that this tissue would interfere with compression of the subtunical vasculature (necessary for maintenance of cavernosal blood for an erection) and predispose the patient to venous leak, marginalizing the effectiveness of any of the aforementioned therapies.
These observations were put into clinical context by Shabsigh et al., 42 who conducted a randomized, controlled trial of testosterone and demand-dose sildenafil versus sildenafil alone for previous PDE-5 inhibitor non-responders. Subjects were followed with serial IIEF scores. Perhaps not surprisingly, patients receiving testosterone repletion sustained a dramatic improvement in response to sildenafil (as assessed by IIEF scores) versus the control group. Patients were followed for only 12 weeks, although the difference in IIEF scores was only significant at 4-week follow-up despite a qualitative difference being observed at all follow-up points. The authors remark that this may be related to the placebo effect within the control group. Perhaps, it is also related to the small sample size and the baseline function of these subjects.
Admittedly, the clinical evidence supporting the role of testosterone for erectile function is in its infancy. However, the early evidence is convincing and small clinical benefits are complemented by molecular rationale. In fact, a dose-dependant relationship between erectile function and testosterone has been suggested, where a critical threshold has been postulated to govern adverse erectile function outcomes. 43 This would imply that normal variations in testosterone, and perhaps even levels below the lower limit of normal, might not compromise erectile function.
Regardless, the impact of testosterone on quality of life in men is well established. 44 We choose to include testosterone replacement in our EP protocol for two important reasons: (1) the scientific rationale that testosterone is key component of erectile function and (2) the overall quality of life improvements are likely to drive sexual interest and compliance with other components of the program. The combination of these factors justifies the role of testosterone in post-RP EP. However, concern regarding testosterone supplementation for men after RP remains controversial. 45, 46 Sexual function assessment tools for clinicians
As the sophistication of ED management has evolved, the need to better characterize and define gradients of erectile function has been critical to advance therapeutic strategies. Additionally, the focus of practitioners has evolved from a narrow scope (for example erectile function) to a more general approach to optimize sexual function (for example satisfaction). Even more recent has been the recognition that the sexual partners and health of the relationship impact outcomes for these patients. Perhaps not surprisingly, female sexual dysfunction has been shown to correlate with male sexual dysfunction, particularly after RP. 47 Furthermore, female sexual function has been reported to improve in prospective studies in which men with ED were treated. 48, 49 Female partner age has even been found to correlate inversely with the ability for post-RP patients to achieve natural erections after surgery. 50 One study has uncovered a potential role for female sexual function as a predictor of compliance with an EP program. 16 We present a list of some of the tools available to clinician to understand baseline sexual function and track the progress of patients (and partners) over therapy. A summary of these tools is also presented in Table 1 .
Relationship Assessment Scale
The relationship assessment scale assesses overall relationship satisfaction with a seven-item measure of general relationship satisfaction. The relationship assessment scale has been used in a wide range of patient populations. Interestingly, it has been specifically used in men with ED. 51 Questions are answered on a five-point Likert scale, with higher scores indicating greater satisfaction.
For men
Erection Hardness Score This single question scoring system has been validated for the assessment of erection hardness. 52 The erection hardness score has demonstrated good test-retest reliability and has correlated well against the pre-specified domains of the IIEF and quality of erection questionnaire.
International Index of Erectile Function
The IIEF is probably the most highly regarded tool for comprehensively assessing erectile function. The survey is a 15-item questionnaire that measures participants' responses on a five-and six-point Likert scale. 53 The tool is broken up into five distinct factors: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall sexual satisfaction. Significant (P-values ¼ 0.0001) changes between baseline and post-treatment scores were identified across all five of the aforementioned domains in the treatment responder cohort as compared with the non-responder cohort in the validation study. A five-item version of the IIEF (IIEF-5 or SHIM) has been introduced and enables a slight more rapid assessment of male sexual health. 54, 55 Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al
For women
Female Sexual Function Index The female sexual function index is a 19-question, 6-domain questionnaire that assess various aspects of female sexual function. 56 Based on clinical interpretations of a principal components analysis, a six-domain structure was identified, which included desire, subjective arousal, lubrication, orgasm, satisfaction and pain. The survey is highly regarded because it covers a broad range of categories relating to female sexual health, although it is difficult to score. It has also been suggested that a cutoff score (26.55) can be used to delineate women at high risk for sexual dysfunction, making this instrument much more efficient to interpret in clinic. 57 Female Sexual Distress Score-Revised The female sexual distress score-revised (FSDS-R) is a 13-question survey that adds a 13th item to the already validated FSDS. 58 In the validation study, mean total FSDS, FSDS-R and FSDS-R item 13 scores with either recall period were significantly higher (Po0.0001) in women with female sexual dysfunction or hypoactive sexual desire disorder than in women with no female sexual dysfunction. This questionnaire offers rapid insight into the desire domain for the sexual partner with more detail than the FSFI desire domain.
Baylor College of Medicine EP Program
There are no standard EP programs and numerous institutions have developed similar variations of this therapeutic strategy. Here, we describe a program currently used at Baylor College of Medicine ('The BCM EP Program'). When reviewing the protocol, it is critical to appreciate that the lack of definitive evidence in support of a singular strategy requires us to consider the incremental value that each therapeutic modality offers. For instance, while the role of the VED in post-RP ED remains controversial, there have been no studies to advo- Figure 1 Overview of introduction, dosage and frequency for the components in the BCM EP program. Note that the diagonal shading implies the therapies are mutually exclusive and only one is used. Abbreviations: PDE-5, phosphodiesterase-5; ICI, intracavernosal injection; MUSE, medicated urethral suppository system; VED, vacuum erection device; TBD, to be determined. Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al Figure 2 Algorithmic overview of the BCM EP program. Abbreviations: PDE-5i, phosphodiesterase-5 inhibitor; ICI, intracavernosal injection; MUSE, medicated urethral suppository system; VED, vacuum erection device; TBD, to be determined; EP, erectile preservation.
Review and treatment protocol: erectile preservation for RP patients DJ Moskovic et al cate against its use and we feel the potential benefits outweigh the cost and time associated with this treatment. Practically, clinicians may choose to adopt parts or all of this strategy that optimize the cost-benefit ratio of the various therapies. In fact, we encourage clinics to critically challenge this protocol and report their experience with some or all of its elements. This will only help refine approaches in the future and optimize function outcomes for patients. Our protocol is premised on daily low-dose PDE-5 inhibitor therapy. There are several reasons for this: (1) most PDE-5 inhibitor studies have been conducted with this therapy and dosing and efficacy are clearly established, (2) the oral route of administration is convenient and comfortable for patients and (3) the upcoming US patent expiration implies that this therapy will be far more price competitive in the future. We recommend patients to take sildenafil on an empty stomach at least 2 h after their most recent meal, although this can be impractical. Sildenafil is used nightly to improve corporal oxygenation. Sexual intercourse is acceptable if the patient is healthy enough to engage in activity, but it is not necessary. It must be stressed that achieving erections is the goal since it is the clear sign of penile oxygenation. Patients who do not respond to the early components of the protocol are quickly identified and transferred to ICI. Figure 1 presents a timeline for the introduction of each of the therapeutic modalities. Quarterly physician visits are recommended to ensure compliance and optimize the therapy for the individual patient. For example, a patient can suggest which therapies are effective and which are bothersome. A decision of which parts of the protocol to adhere can be made in consultation with their treating physician.
Ideally, patients are identified several weeks before RP and introduced to the protocol. If possible, patients are started on low-dose (25 mg) nightly sildenafil and MUSE (250 mg) thrice weekly before surgery. Again, this approach is based on anecdotal data that are unpublished as of this writing. Although this drug is avoided the night before surgery, patients are instructed to resume nightly 25 mg sildenafil 3 days after surgery.
When the foley catheter is removed 7-10 days after surgery, the patient is advised to resume using MUSE three times per week. Patients are again started on 250 mg and escalated to their effective dose if possible. This therapy can often cause urethral burning in patients, is uncomfortable to administer for some, and may be very expensive. For this reason, we recommend its use three times per week and will even discontinue it in some circumstances.
Approximately 1 month after surgery, the patient is re-evaluated. At this visit, they are encouraged to engage in sexual activity. We initiate VED therapy and advise the patient to use the device for 10 min daily. At this point, the patient is on as many as three therapies, although each is distinct in its route of administration, mechanism and timing.
At 3-month post-RP patients who are not responding to nightly sildenafil with MUSE are transitioned to ICI with trimix (phentolamine, papaverine and PGE1). Similar to MUSE, patients are advised to use this treatment three times per week for erections. Patients are trained in our clinic by a physicians' assistant until they show that they can successfully inject themselves. This approach to patient education helps overcome barriers to non-compliance. Screening for testosterone deficiency (if suspected) is performed at this point in addition to regular prostate-specific antigen testing.
The second office visit is also the time where hormone replacement can be initiated if necessary. We recommend that prostate-specific antigen be followed closely over the ensuing visits because of concern for recurrence in the setting of testosterone repletion. Patients are not started on testosterone until two undetectable prostate-specific antigen readings are identified and they have documented symptomatic hypogonadism. Functional erectile status is assessed and patients are challenged to attempt less invasive therapies if the current protocol is effective.
Subsequent visits are scheduled at 3-month intervals where compliance and efficacy are tested. All opportunities to withdraw invasive therapies are attempted, particularly for patients who are experiencing recovery of spontaneous erections. This visit schedule is continued for 18-24 months after surgery to give the patient ample opportunity to respond to therapy. Figure 2 presents a graphical representation of our protocol and providers an algorithm that can be adopted in any practice.
The comprehensive nature of this protocol suggests further study of the relative contribution of each of these therapies be studied. While compliance can be a challenge in these patients, especially because of the out-of-pocket costs associated with EP, we have found that educating the patient on the importance of preserving pre-RP erectile function is the most effective means to overcome non-compliance. Subsequent study of each of these therapies will help clinicians refine their therapies and continue to improve on what is already the 'gold standard' for oncologic outcomes.
